RegeneRx

Shareholder letter - Monday May 13, 2013

Link to document.


RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

March 28, 2014
RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement


March 7, 2014
RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements


February 24, 2014
RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome


January 16, 2014
RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases


January 3, 2014
RegeneRx Receives Orphan Drug Designation for Tß4 in the Treatment of Neurotrophic Keratopathy


December 20, 2013
RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging